Has Mae Sheikh Ali, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,922,508 in general payments to Mae Sheikh Ali, MD across 2,584 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mae Sheikh Ali, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mae Sheikh Ali, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mae Sheikh Ali, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1164405122

Payments from drug & device makers

$2,922,508in general payments, 2019–2025

Across 2,584 payments — averaging $1131.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$1.8M
Novo Nordisk AS$327K
Novo Nordisk$301K
Lilly USA, LLC$144K
Amgen$103K
Abbott$91K
plus $182K from 43 others

$17,547in research payments, 2019–2025

Across 7 payments — averaging $2506.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$18K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	58	$1,774,128
Novo Nordisk AS	1,098	$327,167
Novo Nordisk	441	$301,246
Lilly USA, LLC	169	$144,116
Amgen(2 entities)	161	$102,977
Abbott	231	$90,879
Pfizer	15	$51,979
Mannkind Corporation	75	$25,938
AstraZeneca(2 entities)	31	$19,194
Novartis	7	$17,681
Merck	21	$16,045
Johnson & Johnson	36	$10,926
IBSA Pharma Inc.	25	$10,537
Boehringer Ingelheim	20	$10,236
Boehringer Ingelheim International GmbH	2	$4,975
Radius Health, Inc.	8	$3,892
AbbVie	11	$1,957
Tosoh Bioscience, Inc.	2	$1,566
Valeritas, Inc.	7	$1,309
Neuronetics, Inc.	4	$1,104
Xeris Pharmaceuticals, Inc.	10	$943
Insulet Corporation	49	$898
Zealand Pharma US, Inc.	3	$649
Sanofi-aventis U.S. LLC	20	$391
Medtronic(2 entities)	15	$245
Dexcom, Inc.	12	$229
Bayer	6	$159
Neurocrine Biosciences, Inc.	1	$129
Regeneron Healthcare Solutions, Inc.	1	$120
Madrigal Pharmaceuticals	3	$114
Amarin Pharma, Inc.	6	$106
Corcept Therapeutics	5	$95
Astellas Pharma US Inc	4	$74
Bard Peripheral Vascular, Inc.	1	$57
Tandem Diabetes Care, Inc.	3	$51
Lifescan, Inc.	3	$46
Boston Scientific	2	$37
Shire North American Group Inc	3	$37
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$36
Senseonics, Incorporated	2	$35
Vivus LLC	2	$32
Mayne Pharma Commercial LLC	1	$28
Rhythm Pharmaceuticals, Inc.	1	$26
Sequel Med Tech, LLC	1	$26
UCB, Inc.	1	$23
Kyowa Kirin, Inc.	1	$21
BETA Bionics, Inc.	2	$19
GRT US Holding, Inc.	1	$15
Endo Pharmaceuticals Inc.	1	$13

How this compares

$2,922,508 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024

$21,214

Medicare patients

Services billed

154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jacksonville

David SuttonJacksonville$3.1M
James MageeJacksonville$2.7M
Senan SultanJacksonville$2.5M
J EvansJacksonville$1.7M
Wasim DeebJacksonville$1.5M
Ricardo SilvaJacksonville$867K
Anil ShresthaJacksonville$602K
Joe ChehadeJacksonville$542K
Firas WardaJacksonville$440K
Khurram WadudJacksonville$338K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →